Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TD-4208

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Revefenacin (TD-4208) is a potent, lung-selective, long-acting muscarinic antagonist currently in development as a… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2018
2018
Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in… Expand
Review
2017
Review
2017
ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para… Expand
2014
2014
Introduction TD-4208 is a lung-selective, LAMA shown to have a long duration of action and minimal systemic antimuscarinic… Expand
2013
2013
Tiotropium is currently the only once-daily, long-acting muscarinic antagonist (LAMA) approved in the United States and other… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Review
2013
Review
2013
The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary disease (COPD) is well established… Expand
2012
2012
Background: TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration in… Expand